Aquinox Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
23.54 M |
Public Float |
9.09 M |
Aquinox Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$0.82 |
Market Cap |
$55.55 M |
Shares Outstanding |
23.54 M |
Public Float |
23.39 M |
Address |
887 Great Northern Way Vancouver British Columbia V5T 4T5 Canada |
Employees | - |
Website | http://www.aqxpharma.com |
Updated | 07/08/2019 |
Aquinox Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. |